Intranasal drug developer Impel NeuroPharma has announced the appointment of former MAP Pharmaceuticals President and CEO Timothy S. Nelson as Independent Director of the Board of Directors.
Nelson led MAP Pharmaceuticals when it was acquired by Allergan and served as Chairman of the Board of Civitas Therapeutics when that company was acquired by Acorda. MAP developed Levadex (now Semprana) inhaled dihydroergotamine (DHE) for the treatment of migraine, and Impel is developing an intranasal DHE. Civitas developed inhaled L-dopa for the treatment of Parkinson’s Disease, and Impel is developing an intranasal L-dopa.
Nelson said, “Impel’s unique, cutting-edge technology has the potential to make a substantial step forward in more effective delivery of drugs which can mean better outcomes for millions of patients who are underserved by existing therapies. I am very pleased to be able to contribute to Impel’s mission and growth.”
Impel Founder and CEO John Hoekman commented, “We are very excited to bring Tim onto Impel’s Board of Directors. Tim brings a deep knowledge of both medical devices and pharmaceutical products that will help Impel drive clinical development of our drug-device combination products. Impel is developing nasally administered products to treat migraine, Parkinson’s, and Alzheimer’s disease. Tim’s experience and leadership will help Impel advance these therapies through clinical testing and into the hands of patients.”
Read the Impel NeuroPharma press release.
